Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020

NEXT STORY
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
PREV STORY
Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16

author_avatar
NASDAQ Market News

Telix Pharmaceuticals and German Cancer Research Center (DKFZ) Enter into Collaboration and Option Agreement for Image-Guided Prostate Surgery

author_avatar
NASDAQ Market News

Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

author_avatar
NASDAQ Market News